Technical Analysis for ERAS - Erasca, Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.62 | -0.76% | -0.02 |
ERAS closed down 5.38 percent on Wednesday, November 20, 2024, on 38 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | -0.76% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.76% | |
| Stochastic Reached Oversold | Weakness | -0.76% | |
| Oversold Stochastic | Weakness | -0.76% | |
| 20 DMA Resistance | Bearish | -6.09% | |
| Crossed Above 50 DMA | Bullish | -6.09% | |
| Inside Day | Range Contraction | -6.09% | |
| 20 DMA Resistance | Bearish | -4.03% | |
| 50 DMA Resistance | Bearish | -4.03% | |
| Gapped Up | Strength | -4.03% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
| Down 3% | about 3 hours ago |
| Bearish 180 Entry | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Ras Gtpase Bemcentinib Ptpn11
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Ras Gtpase Bemcentinib Ptpn11
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.45 |
| 52 Week Low | 1.51 |
| Average Volume | 1,922,373 |
| 200-Day Moving Average | 2.47 |
| 50-Day Moving Average | 2.76 |
| 20-Day Moving Average | 2.83 |
| 10-Day Moving Average | 2.88 |
| Average True Range | 0.20 |
| RSI (14) | 43.18 |
| ADX | 14.79 |
| +DI | 19.10 |
| -DI | 20.38 |
| Chandelier Exit (Long, 3 ATRs) | 2.69 |
| Chandelier Exit (Short, 3 ATRs) | 3.05 |
| Upper Bollinger Bands | 3.20 |
| Lower Bollinger Band | 2.45 |
| Percent B (%b) | 0.25 |
| BandWidth | 26.69 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0347 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.97 | ||||
| Resistance 3 (R3) | 2.99 | 2.91 | 2.92 | ||
| Resistance 2 (R2) | 2.91 | 2.82 | 2.90 | 2.90 | |
| Resistance 1 (R1) | 2.77 | 2.77 | 2.73 | 2.75 | 2.88 |
| Pivot Point | 2.69 | 2.69 | 2.67 | 2.68 | 2.69 |
| Support 1 (S1) | 2.55 | 2.60 | 2.51 | 2.53 | 2.40 |
| Support 2 (S2) | 2.47 | 2.55 | 2.46 | 2.38 | |
| Support 3 (S3) | 2.33 | 2.47 | 2.37 | ||
| Support 4 (S4) | 2.31 |
